X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) COO Mary Dibiase sold 67,695 shares of the company's stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $0.57, for a total transaction of $38,586.15. Following the completion of the sale, the chief operating officer now directly owns 452,060 shares in the company, valued at approximately $257,674.20. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
X4 Pharmaceuticals Price Performance
NASDAQ:XFOR opened at $0.54 on Wednesday. The firm has a market cap of $90.85 million, a PE ratio of -0.77 and a beta of 0.36. X4 Pharmaceuticals, Inc. has a 12 month low of $0.51 and a 12 month high of $1.60. The company has a quick ratio of 6.04, a current ratio of 6.07 and a debt-to-equity ratio of 0.79. The company's 50-day moving average price is $0.68 and its two-hundred day moving average price is $0.90.
X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.07) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.03). The business had revenue of $0.56 million for the quarter, compared to analysts' expectations of $52.98 million. During the same quarter in the previous year, the business posted ($0.33) EPS. On average, equities analysts anticipate that X4 Pharmaceuticals, Inc. will post -0.65 EPS for the current fiscal year.
Hedge Funds Weigh In On X4 Pharmaceuticals
Watch this before it gets removed
From Porter & Company | Ad
If you missed it, my emergency election broadcast is now available - but will be removed soon
Click here to watch it now.
Large investors have recently modified their holdings of the stock. Kingdon Capital Management L.L.C. lifted its position in shares of X4 Pharmaceuticals by 76.0% during the fourth quarter. Kingdon Capital Management L.L.C. now owns 3,473,683 shares of the company's stock worth $2,913,000 after purchasing an additional 1,500,000 shares in the last quarter. Ensign Peak Advisors Inc lifted its position in shares of X4 Pharmaceuticals by 4.6% during the second quarter. Ensign Peak Advisors Inc now owns 2,546,458 shares of the company's stock worth $1,477,000 after purchasing an additional 111,032 shares in the last quarter. Rhumbline Advisers lifted its position in shares of X4 Pharmaceuticals by 14.6% during the second quarter. Rhumbline Advisers now owns 187,246 shares of the company's stock worth $109,000 after purchasing an additional 23,831 shares in the last quarter. K2 Principal Fund L.P. acquired a new position in shares of X4 Pharmaceuticals during the second quarter worth approximately $284,000. Finally, XTX Topco Ltd acquired a new position in shares of X4 Pharmaceuticals during the second quarter worth approximately $65,000. 72.03% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Separately, HC Wainwright reissued a "buy" rating and issued a $5.00 target price on shares of X4 Pharmaceuticals in a research note on Friday, June 28th.
Check Out Our Latest Report on X4 Pharmaceuticals
X4 Pharmaceuticals Company Profile
(
Get Free Report)
X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
